All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Clearance of somatic mutations at complete remission (CR), particularly in non-preleukemic genes, associated with a better survival and a reduced risk of relapse in patients with acute myeloid leukemia (AML), according to a study published in the Journal of Clinical Oncology by Kiyomi Morita and colleagues from The University Texas MD Anderson Cancer Center, Houston, US.
Predicting the risk of relapse is a significant challenge in AML. The researchers at the MDACC aimed to investigate whether the degree of mutation clearance (MC) at remission can predict relapse in AML patients.
The authors retrospectively performed DNA sequencing on pre-treatment and CR samples, collected from a total of 131 patients (median age = 51 years, IQR: 39–55) with AML who were treated with frontline intensive induction chemotherapy (frontline idarubicin plus cytarabine-based) and attained morphologic CR at Day 30. Three levels of MC were defined based on the variant allele frequency (VAF) of residual mutations at CR including MC2.5 (if at least one mutation persisted with a VAF of 2.5%), MC1.0 (if at least one mutation persisted with a VAF of 1%) and complete mutation clearance (CMC, if there were no persistent mutations).
The authors noted that their study supports “a proof of concept that somatic mutations, particularly non-preleukemic mutations, can serve as molecular minimal residual disease (MRD) markers in AML”. They further added that “MC may be a promising tool with which to identify patients with AML who are at high risk of relapse, and should be explored, along with a flow MRD, as an MRD marker in AML.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox